Literature DB >> 21248682

Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

Anthony E Fiore1, Alicia Fry, David Shay, Larisa Gubareva, Joseph S Bresee, Timothy M Uyeki.   

Abstract

This report updates previous recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of antiviral agents for the prevention and treatment of influenza (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2008;57[No. RR-7]).This report contains information on treatment and chemoprophylaxis of influenza virus infection and provides a summary of the effectiveness and safety of antiviral treatment medications. Highlights include recommendations for use of 1) early antiviral treatment of suspected or confirmed influenza among persons with severe influenza (e.g., those who have severe, complicated, or progressive illness or who require hospitalization); 2) early antiviral treatment of suspected or confirmed influenza among persons at higher risk for influenza complications; and 3) either oseltamivir or zanamivir for persons with influenza caused by 2009 H1N1 virus, influenza A (H3N2) virus, or influenza B virus or when the influenza virus type or influenza A virus subtype is unknown; 4) antiviral medications among children aged <1 year; 5) local influenza testing and influenza surveillance data, when available, to help guide treatment decisions; and 6) consideration of antiviral treatment for outpatients with confirmed or suspected influenza who do not have known risk factors for severe illness, if treatment can be initiated within 48 hours of illness onset. Additional information is available from CDC's influenza website at http://www.cdc.gov/flu, including any updates or supplements to these recommendations that might be required during the 2010-11 influenza season. Health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information. Recommendations related to the use of vaccines for the prevention of influenza during the 2010-11 influenza season have been published previously (CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP], 2010. MMWR 2010;59[No. RR-8]).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248682

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  310 in total

1.  Assessment of Test Performance and Potential for Environmental Contamination Associated with a Point-of-Care Molecular Assay for Group A Streptococcus in an End User Setting.

Authors:  Leslie J Donato; Nikki K Myhre; Martha A Murray; Margaret R McDonah; Jane F Myers; Julie A Maxson; Alicia M Meek; Mark J Espy; Joseph W Furst; Brad S Karon; Matthew J Binnicker
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

2.  Children with special health care needs and preparedness: experiences from seasonal influenza and the 2009 H1N1 influenza pandemic.

Authors:  Georgina Peacock; Cynthia Moore; Timothy Uyeki
Journal:  Disaster Med Public Health Prep       Date:  2012-06       Impact factor: 1.385

3.  Clinical and demographic characteristics of seasonal influenza in pediatric patients with cancer.

Authors:  Silvana B Carr; Elisabeth E Adderson; Hana Hakim; Xiaoping Xiong; Xiaowei Yan; Miguela Caniza
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

4.  Novel Polyanions Inhibiting Replication of Influenza Viruses.

Authors:  Justyna Ciejka; Aleksandra Milewska; Magdalena Wytrwal; Jacek Wojarski; Anna Golda; Marek Ochman; Maria Nowakowska; Krzysztof Szczubialka; Krzysztof Pyrc
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 5.  Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.

Authors:  Stephanie Charshafian; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-06-11       Impact factor: 2.264

6.  Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.

Authors:  Cong Thanh Nguyen; Saori Suzuki; Yasushi Itoh; Hirohito Ishigaki; Misako Nakayama; Kaori Hayashi; Keita Matsuno; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Authors:  E Bart Tarbet; Stephanie Hamilton; Almut H Vollmer; Angela Luttick; Wy Ching Ng; Melinda Pryor; Brett L Hurst; Simon Crawford; Donald F Smee; Simon P Tucker
Journal:  J Antimicrob Chemother       Date:  2014-04-28       Impact factor: 5.790

8.  T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.

Authors:  Tatiana Baranovich; Sook-San Wong; Jianling Armstrong; Henju Marjuki; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  The authors reply.

Authors:  Justin R Ortiz; Kathleen M Neuzil; Colin R Cooke
Journal:  Crit Care Med       Date:  2015-04       Impact factor: 7.598

Review 10.  Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Authors:  Deeva Berera; Maria Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.